Celldex Therapeutics (CLDX) Retained Earnings (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Retained Earnings of $2.5 million for Q1 2026, down 29.32% year-over-year from $3.6 million in Q1 2025, and down 30.45% quarter-over-quarter from $3.6 million in Q4 2025.
Celldex Therapeutics (CLDX) Retained Earnings (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 29.32% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (down 29.32% YoY), while the FY2025 annual figure was $3.6 million, up 100.23% from the prior year.
- Retained Earnings for Q1 2026 stood at $2.5 million, down from $3.6 million in the prior quarter.
- The five-year high for Retained Earnings was $5.3 million in Q3 2024, with the low at -$1.7 billion in Q3 2025.
- The 5-year median for Retained Earnings is -$417000.0 (2022), against an average of -$679.6 million.
- Peak annual rise in Retained Earnings reached 1795.54% in 2023, while the deepest fall reached 315438.37% in 2023.
- Celldex Therapeutics' Retained Earnings stood at -$1.3 billion in 2022, then surged by 100.26% to $3.3 million in 2023, then tumbled by 47114.03% to -$1.6 billion in 2024, then jumped by 100.23% to $3.6 million in 2025, then plunged by 30.45% to $2.5 million in 2026.
- Business Quant data shows CLDX's Retained Earnings at $2.5 million in Q1 2026, $3.6 million in Q4 2025, and -$1.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -1.97 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.97 Bn |
| Mar 31, 2026 | 2.52 Mn |
| Dec 31, 2025 | 3.63 Mn |
| Sep 30, 2025 | -1.73 Bn |
| Jun 30, 2025 | -1.67 Bn |
| Mar 31, 2025 | 3.57 Mn |
| Dec 31, 2024 | -1.56 Bn |
| Sep 30, 2024 | 5.29 Mn |
| Jun 30, 2024 | -1.47 Bn |
| Mar 31, 2024 | 2.24 Mn |
| Dec 31, 2023 | 3.31 Mn |
| Sep 30, 2023 | -1.35 Bn |
| Jun 30, 2023 | -1.32 Bn |
| Mar 31, 2023 | 2.12 Mn |
| Dec 31, 2022 | -1.26 Bn |
| Sep 30, 2022 | -1.23 Bn |
| Jun 30, 2022 | -417,000.00 |
| Mar 31, 2022 | 112,000.00 |
| Dec 31, 2021 | 1.89 Mn |
| Sep 30, 2021 | -1.12 Bn |